Roche’s Lung Cancer Drug Combination Shows Promising Results

1 Mins read

Shares of Roche Holding have surged following the release of interim results from a late-stage clinical trial involving a combination of two of its drugs for lung cancer patients. The trial demonstrated a benefit for overall survival, leading to a 4.5% increase in Roche’s nonvoting shares.

Positive Interim Results

According to Roche, patients who received the immunotherapy tiragolumab in combination with the antibody Tecentriq showed an estimated median overall survival of 22.9 months. In comparison, patients who received Tecentriq alone had a median overall survival of 16.7 months. However, Roche advises caution as these results are still considered immature.

Potential Overall Survival Benefit

Citi analysts have stated that the ongoing phase 3 trial is on track to show a significant overall survival benefit. However, there are concerns regarding the data from the arm of the trial that received Tecentriq alone. Roche failed to replicate the median survival rate previously achieved in another trial with Tecentriq, which may limit its commercial impact.

Unintended Data Disclosure

Roche provided this progress update following an inadvertent disclosure of analysis data. The trial remains blinded to both patients and investigators and will continue until the final analysis for overall survival is completed. The company expects to release the final analysis in December.

It is worth highlighting that the initial goal of the lung-cancer trial was to achieve progression-free survival. Although this target was not met, the positive results for overall survival offer hope for lung cancer patients.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *